German multinational life sciences company operating in pharmaceuticals, consumer health, and crop science.Yahoo Finance ↗bayer.com ↗
1 take · first discussed May 1, 2026
Commentary only — they've discussed this name but haven't made a call on it, so we don't attribute any call return to it. The stock's price chart and the takes are below.
The price since they started discussing it. Click a mention to see where it stood — these are comments, not calls.
The sole host view on Bayer comes from Friedberg, who holds a neutral, medium-conviction stance driven almost entirely by the company's Roundup litigation overhang. He highlights that Bayer has already paid $10B and reserved another $10B, with 90,000 cases still outstanding, and flags that the pivotal Supreme Court ruling — once expected to be a clear 6-3 win for Bayer — now looks like a 50-50 coin flip, potentially a 5-4 decision either way. This unresolved legal uncertainty is the central factor shaping his cautious view, and no other hosts provided a thesis to agree or disagree with his assessment.
Friedberg describes Bayer's massive Roundup litigation exposure — $10B paid, $10B reserved, 90,000 cases outstanding — noting the Supreme Court case outcome is now a coin flip rather than the expected 6-3 Bayer win, creating significant uncertainty for the stock.
They have 90,000 cases still outstanding in the courts...going into it, we were kind of like trying to say, hey, maybe this could be 6-3. So honestly...this could be a 50-50 coin flip, 5-4 either way.”1:11:25